Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer

Journal of Biological Chemistry

Volumn 288, Issue 23, 2013, Pages 16476-16483

  Yang, Dong Rong ^a,b   Ding, Xian Fan ^a,c   Luo, Jie ^a   Shan, Yu Xi ^b   Wang, Ronghao ^a   Lin, Shin Jen ^a   Li, Gonghui ^c   Huang, Chiung Kuei ^a   Zhu, Jin ^a,b   Chen, Yuhchyau ^a   Lee, Soo Ok ^b   Chang, Chawnshang ^a,d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b SOOCHOW UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOSENSITIVITY; CHEMOTHERAPEUTIC DRUGS; DRUG SENSITIVITY; INTERLEUKIN-1 RECEPTOR ANTAGONISTS; MOLECULAR MECHANISM; NUCLEAR RECEPTORS; PROSTATE CANCERS; RECEPTOR ANTAGONISTS;

CELL CULTURE; CELL DEATH; DISEASES;

STEM CELLS;

CD133 ANTIGEN; CELL PROTEIN; DOCETAXEL; ETOPOSIDE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; OCTAMER TRANSCRIPTION FACTOR 4; TESTICULAR NUCLEAR RECEPTOR 4; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL POPULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; UPREGULATION;

CANCER STEM CELLS; CHEMORESISTANCE; DRUG RESISTANCE; NUCLEAR RECEPTORS; OCT4; PROSTATE CANCER; TESTICULAR ORPHAN NUCLEAR RECEPTOR 4;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLYCOPROTEINS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PEPTIDES; PROSTATIC NEOPLASMS; RECEPTORS, STEROID; RECEPTORS, THYROID HORMONE; TAXOIDS;

EID: 84878765030     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.448142     Document Type: Article

References (56)

1. Siegel, R., Naishadham, D., and Jemal, A. (2012) Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29
2. Seruga, B., and Tannock, I. F. (2011) Chemotherapy-based treatment for castration-resistant prostate cancer. J. Clin. Oncol. 29, 3686-3694
3. Hwang, C. (2012) Overcoming docetaxel resistance in prostate cancer. A perspective review. Ther. Adv. Med. Oncol. 4, 329-340
4. Colloca, G., Venturino, A., and Checcaglini, F. (2012) Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer.Areview. Med. Oncol. 29, 776-785
5. Ross, R. W., Beer, T. M., Jacobus, S., Bubley, G. J., Taplin, M. E., Ryan, C. W., Huang, J., and Oh, W. K. (2008) A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 112, 521-526 (Pubitemid 351186193)
6. Nakabayashi, M., Sartor, O., Jacobus, S., Regan, M. M., McKearn, D., Ross, R. W., Kantoff, P. W., Taplin, M. E., and Oh, W. K. (2008) Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 101, 308-312
7. Reuter, C. W., Morgan, M. A., Ivanyi, P., Fenner, M., Ganser, A., and Grünwald, V. (2010) Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. World J. Urol. 28, 391-398
8. Caffo, O., Sava, T., Comploj, E., Giampaolo, M. A., Segati, R., Valduga, F., Cetto, G., and Galligioni, E. (2010) Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol. Oncol. 28, 152-156
9. Beer, T. M., Ryan, C. W., Venner, P. M., Petrylak, D. P., Chatta, G. S., Ruether, J. D., Chi, K. N., Young, J., and Henner, W. D. (2008) Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer. Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112, 326-330
10. Rosenberg, J. E., Ryan, C. J., Weinberg, V. K., Smith, D. C., Hussain, M., Beer, T. M., Ryan, C. W., Mathew, P., Pagliaro, L. C., Harzstark, A. L., Sharib, J., and Small, E. J. (2009) Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. A study of the Department of Defense prostate cancer clinical trials consortium. J. Clin. Oncol. 27, 2772-2778
11. Michels, J., Montemurro, T., Murray, N., Kollmannsberger, C., and Nguyen Chi, K. (2006) First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer. Does sequence matter? Cancer 106, 1041-1046
12. v integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann. Oncol. 24, 329-336
13. Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., Carles, J., Mulders, P. F., Basch, E., Small, E. J., Saad, F., Schrijvers, D., Van Poppel, H., Mukherjee, S. D., Suttmann, H., Gerritsen, W. R., Flaig, T. W., George, D. J., Yu, E. Y., Efstathiou, E., Pantuck, A., Winquist, E., Higano, C. S., Taplin, M. E., Park, Y., Kheoh, T., Griffin, T., Scher, H. I., and Rathkopf, D. E. (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148
14. Mezynski, J., Pezaro, C., Bianchini, D., Zivi, A., Sandhu, S., Thompson, E., Hunt, J., Sheridan, E., Baikady, B., Sarvadikar, A., Maier, G., Reid, A. H., Mulick Cassidy, A., Olmos, D., Attard, G., and de Bono, J. (2012) Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone. Clinical evidence for cross-resistance? Ann. Oncol. 23, 2943-2947
15. Sternberg, C. N., Molina, A., North, S., Mainwaring, P., Fizazi, K., Hao, Y., Rothman, M., Gagnon, D. D., Kheoh, T., Haqq, C. M., Cleeland, C., de Bono, J. S., and Scher, H. I. (2013) Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann. Oncol. 24, 1017-1025
16. Loriot, Y., Massard, C., Gross-Goupil, M., Di Palma, M., Escudier, B., Bossi, A., Chauchereau, A., and Fizazi, K. (2010) The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur. J. Cancer 46, 1770-1772
17. Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., and Maitland, N. J. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946-10951 (Pubitemid 41713363)
18. Linn, D. E., Yang, X., Sun, F., Xie, Y., Chen, H., Jiang, R., Chen, H., Chumsri, S., Burger, A. M., and Qiu, Y. (2010) A role for OCT4 in tumor initiation of drug-resistant prostate cancer cells. Genes Cancer 1, 908-916
19. Maitland, N. J., and Collins, A. (2005) A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int. 96, 1219-1223 (Pubitemid 41743913)
20. Crea, F., Danesi, R., and Farrar, W. L. (2009) Cancer stem cell epigenetics and chemoresistance. Epigenomics 1, 63-79
21. Dean, M., Fojo, T., and Bates, S. (2005) Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (Pubitemid 40488633)
22. Frame, F. M., and Maitland, N. J. (2011) Cancer stem cells, models of study and implications of therapy resistance mechanisms. Adv. Exp. Med. Biol. 720, 105-118
23. Chang, C., Da Silva, S. L., Ideta, R., Lee, Y., Yeh, S., and Burbach, J. P. (1994) Human and rat TR4 orphan receptors specify a subclass of the steroid receptor superfamily. Proc. Natl. Acad. Sci. U.S.A. 91, 6040-6044 (Pubitemid 24188278)
24. Yan, S. J., Lee, Y. F., Ting, H. J., Liu, N. C., Liu, S., Lin, S. J., Yeh, S. D., Li, G., and Chang, C. (2012) Deficiency in TR4 nuclear receptor abrogates Gadd45a expression and increases cytotoxicity induced by ionizing radiation. Cell. Mol. Biol. Lett. 17, 309-322
25. Kim, E., Ma, W. L., Lin, D. L., Inui, S., Chen, Y. L., and Chang, C. (2007) TR4 orphan nuclear receptor functions as an apoptosis modulator via regulation of Bcl-2 gene expression. Biochem. Biophys. Res. Commun. 361, 323-328 (Pubitemid 47187262)
26. Liu, S., Yan, S. J., Lee, Y. F., Liu, N. C., Ting, H. J., Li, G., Wu, Q., Chen, L. M., and Chang, C. (2011) Testicular nuclear receptor 4 (TR4) regulates UV light-induced responses via Cockayne syndrome B protein-mediated transcription-coupled DNA repair. J. Biol. Chem. 286, 38103-38108
27. Lee, Y. F., Liu, S., Liu, N. C., Wang, R. S., Chen, L. M., Lin, W. J., Ting, H. J., Ho, H. C., Li, G., Puzas, E. J., Wu, Q., and Chang, C. (2011) Premature aging with impaired oxidative stress defense in mice lacking TR4. Am. J. Physiol. Endocrinol. Metab. 301, E91-E98
28. Malik, B., and Nie, D. (2012) Cancer stem cells and resistance to chemo and radio therapy. Front. Biosci. (Elite Ed.) 4, 2142-2149
29. Morrison, R., Schleicher, S. M., Sun, Y., Niermann, K. J., Kim, S., Spratt, D. E., Chung, C. H., and Lu, B. (2011) Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J. Oncol. 2011, 941876
30. Klarmann, G. J., Hurt, E. M., Mathews, L. A., Zhang, X., Duhagon, M. A., Mistree, T., Thomas, S. B., and Farrar, W. L. (2009) Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin. Exp. Metastasis 26, 433-446
31. Kawasaki, B. T., Hurt, E. M., Kalathur, M., Duhagon, M. A., Milner, J. A., Kim, Y. S., and Farrar, W. L. (2009) Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells. An integrated molecular profiling approach. Prostate 69, 827-837
32. Duhagon, M. A., Hurt, E. M., Sotelo-Silveira, J. R., Zhang, X., and Farrar, W. L. (2010) Genomic profiling of tumor initiating prostatospheres. BMC Genomics 11, 324
33. Wang, X. Q., Ongkeko, W. M., Chen, L., Yang, Z. F., Lu, P., Chen, K. K., Lopez, J. P., Poon, R. T., and Fan, S. T. (2010) Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 52, 528-539
34. Tsai, L. L., Yu, C. C., Chang, Y. C., Yu, C. H., and Chou, M. Y. (2011) Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J. Oral Pathol. Med. 40, 621-628
35. Wen, K., Fu, Z., Wu, X., Feng, J., Chen, W., and Qian, J. (2013) Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells. Effects associated with STAT3/Survivin. Cancer Lett. 333, 56-65
36. Shyr, C. R., Kang, H. Y., Tsai, M. Y., Liu, N. C., Ku, P. Y., Huang, K. E., and Chang, C. (2009) Roles of testicular orphan nuclear receptors 2 and 4 in early embryonic development and embryonic stem cells. Endocrinology 150, 2454-2462
37. Greco, S. J., Liu, K., and Rameshwar, P. (2007) Functional similarities among genes regulated by OCT4 in human mesenchymal and embryonic stem cells. Stem Cells 25, 3143-3154 (Pubitemid 350294440)
38. Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., and Tannock, I. F. (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. Updated survival in the TAX 327 study. J. Clin. Oncol. 26, 242-245
39. James, N. D., Sydes, M. R., Mason, M. D., Clarke, N. W., Anderson, J., Dearnaley, D. P., Dwyer, J., Jovic, G., Ritchie, A. W., Russell, J. M., Sanders, K., Thalmann, G. N., Bertelli, G., Birtle, A. J., O'Sullivan, J. M., Protheroe, A., Sheehan, D., Srihari, N., and Parmar, M. K. (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer. First results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 13, 549-558
40. Smith, D. C., Tangen, C. M., Van Veldhuizen, P. J., Jr., Harrer, G. W., Golshayan, A., Mills, G. M., Vogelzang, N. J., Thompson, I. M., and Hussain, M. H. (2011) Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma. Southwest Oncology Group S0032. Urology 77, 1172-1176
41. Matsumoto, A., Inoue, A., Yokoi, S., Nozumi, K., Miyazaki, K., Hosoki, S., Nagata, M., and Yamaguchi, K. (2009) Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Int. J. Urol. 16, 687-691
42. Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., Rosenthal, M. A., Eisenberger, M. A., and TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (Pubitemid 39315317)
43. Yap, T. A., Pezaro, C. J., and de Bono, J. S. (2012) Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Rev. Anticancer Ther. 12, 1129-1136
44. Heidenreich, A., Scholz, H. J., Rogenhofer, S., Arsov, C., Retz, M., Müller, S. C., Albers, P., Gschwend, J., Wirth, M., Steiner, U., Miller, K., Heinrich, E., Trojan, L., Volkmer, B., Honecker, F., Bokemeyer, C., Keck, B., Otremba, B., Ecstein-Fraisse, E., and Pfister, D. (2013) Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel. Results from the German compassionate-use programme. Eur. Urol. 63, 977-982
45. Mimeault, M., Johansson, S. L., and Batra, S. K. (2012) Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies. PloS One 7, e31919
46. Liu, T., Xu, F., Du, X., Lai, D., Liu, T., Zhao, Y., Huang, Q., Jiang, L., Huang, W., Cheng, W., and Liu, Z. (2010) Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stemlike cells from human prostate cancer cell lines 22RV1. Mol. Cell. Biochem. 340, 265-273
47. Zhang, L., Jiao, M., Li, L., Wu, D., Wu, K., Li, X., Zhu, G., Dang, Q., Wang, X., Hsieh, J. T., and He, D. (2012) Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J. Cancer Res. Clin. Oncol. 138, 675-686
48. Fan, X., Liu, S., Su, F., Pan, Q., and Lin, T. (2012) Effective enrichment of prostate cancer stem cells from spheres in a suspension culture system. Urol. Oncol. 30, 314-318
49. Harper, L. J., Costea, D. E., Gammon, L., Fazil, B., Biddle, A., and Mackenzie, I. C. (2010) Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer 10, 166
50. Yan, H., Chen, X., Zhang, Q., Qin, J., Li, H., Liu, C., Calhoun-Davis, T., Coletta, L. D., Klostergaard, J., Fokt, I., Skora, S., Priebe, W., Bi, Y., and Tang, D. G. (2011) Drug-tolerant cancer cells show reduced tumor-initiating capacity. Depletion of CD44 cells and evidence for epigenetic mechanisms. PloS One 6, e24397
51. Thomas, S., and Shah, G. (2005) Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. Cancer Biol. Ther. 4, 1226-1233
52. Yin, S., Dong, Y., Li, J., Fan, L., Wang, L., Lu, J., Vang, O., and Hu, H. (2012) Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad. Apoptosis 17, 388-399
53. Gan, L., Wang, J., Xu, H., and Yang, X. (2011) Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate 71, 1158-1166
54. Hawley, S. A., Gadalla, A. E., Olsen, G. S., and Hardie, D. G. (2002) The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51, 2420-2425 (Pubitemid 34827390)
55. Kim, E., Liu, N. C., Yu, I. C., Lin, H. Y., Lee, Y. F., Sparks, J. D., Chen, L. M., and Chang, C. (2011) Metformin inhibits nuclear receptor TR4-mediated hepatic stearoyl-CoA desaturase 1 gene expression with altered insulin sensitivity. Diabetes 60, 1493-1503
56. Dinarello, C. A. (2010) Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 29, 317-329